Solid Biosciences Inc (NASDAQ:SLDB) major shareholder Boxer Capital, Llc sold 450,000 shares of the business’s stock in a transaction dated Thursday, March 28th. The stock was sold at an average price of $9.88, for a total value of $4,446,000.00. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.
NASDAQ SLDB traded up $0.41 on Friday, reaching $9.21. The stock had a trading volume of 500,581 shares, compared to its average volume of 414,230. The company has a current ratio of 10.31, a quick ratio of 10.31 and a debt-to-equity ratio of 0.01. Solid Biosciences Inc has a 12-month low of $5.97 and a 12-month high of $54.84. The stock has a market cap of $326.25 million, a P/E ratio of -4.09 and a beta of 1.83.
Solid Biosciences (NASDAQ:SLDB) last issued its quarterly earnings data on Wednesday, March 13th. The company reported ($0.67) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.58) by ($0.09). As a group, research analysts predict that Solid Biosciences Inc will post -2.53 earnings per share for the current year.
A number of brokerages have recently commented on SLDB. ValuEngine downgraded Solid Biosciences from a “buy” rating to a “hold” rating in a research report on Tuesday, April 9th. Zacks Investment Research upgraded Solid Biosciences from a “hold” rating to a “buy” rating and set a $8.25 target price for the company in a research note on Wednesday, February 13th. Chardan Capital restated a “buy” rating and set a $15.00 target price on shares of Solid Biosciences in a research note on Thursday, February 7th. Svb Leerink cut Solid Biosciences from an “outperform” rating to a “market perform” rating in a research note on Friday, February 8th. Finally, Citigroup upgraded Solid Biosciences from a “sell” rating to a “neutral” rating and set a $8.00 target price for the company in a research note on Friday, February 8th. Seven analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $29.38.
TRADEMARK VIOLATION NOTICE: This article was originally published by Baseball Daily News and is owned by of Baseball Daily News. If you are viewing this article on another domain, it was copied illegally and republished in violation of international trademark & copyright legislation. The original version of this article can be accessed at https://www.baseballdailydigest.com/news/2019/04/21/solid-biosciences-inc-sldb-major-shareholder-boxer-capital-llc-sells-450000-shares.html.
About Solid Biosciences
Solid Biosciences Inc engages in identifying and developing therapies for duchenne muscular dystrophy in the United States. Its lead product candidate includes SGT-001, a gene therapy that is in Phase I/II clinical trials to restore functional dystrophin protein expression in patients' muscles. The company's product candidates also comprise SB-001, a monoclonal antibody to reduce fibrosis and inflammation.
Featured Article: Risk Tolerance and Your Investment Decisions
Receive News & Ratings for Solid Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solid Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.